LONDON, April 22, 2014 /PRNewswire/ --
On Monday, April 21, 2014, the NASDAQ Composite ended at 4,121.55, up 0.64%, the Dow Jones Industrial Average advanced 0.25% to 16,449.25, and the S&P 500 closed at 1,871.89, up 0.38%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 666.48, up 1.20%, while the same has declined 3.26% in the last one month. Investor-Edge has initiated coverage on the following equities: MEDNAX Inc. (NYSE: MD), Covance Inc. (NYSE: CVD), PAREXEL International Corp. (NASDAQ: PRXL) and Charles River Laboratories International Inc. (NYSE: CRL). Free technical research on MD, CVD, PRXL and CRL can be downloaded upon signing up at:
MEDNAX Inc.'s stock gone-up 0.33% on Monday, closing at $60.65, after oscillating between $60.18 and $60.85. A total of 0.30 million shares were traded, which was much below its three months average volume of 0.63 million shares. Over the past three trading sessions and previous three months, MEDNAX Inc.'s shares have advanced 1.13% and 9.69%, respectively. Also, since the beginning of this year, the company's stock has rallied 13.62%. The company's stock is trading above its 200-day moving average. MEDNAX Inc.'s 50-day moving average of $61.02 is above its 200-day moving average of $54.08. Furthermore, the company's stock is trading at a PE ratio of 21.86 and has a Relative Strength Index (RSI) of 44.07. Sign up today to read free research on MD at:
Covance Inc.'s shares witnessed a trading volume of 0.31 million shares on Monday, which was below its three months average volume of 0.47 million shares. The stock ended the day at $97.52, up 0.57%, after trading between $96.33 and $97.64. Over the last three months and since the start of this year, shares in Covance Inc. have gained 2.48% and 10.74%, respectively. However, during the last one month, the company's stock has fallen by 5.50%. The stock is trading above its 200-day moving average. Covance Inc.'s 50-day moving average of $101.91 is above its 200-day moving average of $89.97. Additionally, the company's shares are trading at a PE ratio of 29.97 and have an RSI of 39.75. Sign up today to read free research on CVD at:
On Monday, shares in PAREXEL International Corp. advanced 0.20% finishing the session at $50.25. The stock recorded a trading volume of 0.30 million shares which was below its three months average volume of 0.52 million shares. The stock fluctuated between $49.91 and $50.53 during the session. Over the past three trading sessions and last three months, PAREXEL International Corp.'s shares have gained 2.01% and 9.24%, respectively. Also, since the beginning of this year, the company's stock has surged 11.22%. The stock is trading above its 200-day moving average. PAREXEL International Corp.'s 50-day moving average of $53.10 is above its 200-day moving average of $48.79. Moreover, the company's shares are trading at a PE ratio of 25.59 and have an RSI of 41.51. Sign up today to read free research on PRXL at:
Shares in Charles River Laboratories International Inc. recorded a trading volume of 0.40 million shares, as compared with its three months average volume of 0.58 million shares. The stock ended Monday's session at $57.97, up 1.54%, and registered an intraday trading range of $56.93 and $58.20. Over the past three trading sessions and beginning of this year, shares of Charles River Laboratories International Inc. have advanced 2.06% and 9.29%, respectively. However, over the last one month, the company's stock has lost 4.70%. The stock is trading above its 200-day moving average. Charles River Laboratories International Inc.'s 50-day moving average of $59.04 is above its 200-day moving average of $51.90. Moreover, the company's shares are trading at a PE ratio of 21.81 and have an RSI of 42.52. Sign up today to read free research on CRL at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.